3,894 research outputs found
Coupling models of cattle and farms with models of badgers for predicting the dynamics of bovine tuberculosis (TB)
Bovine TB is a major problem for the agricultural industry in several
countries. TB can be contracted and spread by species other than cattle and
this can cause a problem for disease control. In the UK and Ireland, badgers
are a recognised reservoir of infection and there has been substantial
discussion about potential control strategies. We present a coupling of
individual based models of bovine TB in badgers and cattle, which aims to
capture the key details of the natural history of the disease and of both
species at approximately county scale. The model is spatially explicit it
follows a very large number of cattle and badgers on a different grid size for
each species and includes also winter housing. We show that the model can
replicate the reported dynamics of both cattle and badger populations as well
as the increasing prevalence of the disease in cattle. Parameter space used as
input in simulations was swept out using Latin hypercube sampling and
sensitivity analysis to model outputs was conducted using mixed effect models.
By exploring a large and computationally intensive parameter space we show that
of the available control strategies it is the frequency of TB testing and
whether or not winter housing is practised that have the most significant
effects on the number of infected cattle, with the effect of winter housing
becoming stronger as farm size increases. Whether badgers were culled or not
explained about 5%, while the accuracy of the test employed to detect infected
cattle explained less than 3% of the variance in the number of infected cattle
Recommended from our members
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB) treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB patients. Recently, several clinical trials of "universal" drug regimens, aiming to treat drug-susceptible and drug-resistant TB, have included a fluoroquinolone. In the absence of clinical data comparing their side-by-side efficacies in controlled MDR-TB trials, a pharmacological rationale is needed to guide the selection of the most efficacious fluoroquinolone. The present studies were designed to test the hypothesis that fluoroquinolone concentrations (pharmacokinetics) and activity (pharmacodynamics) at the site of infection are better predictors of efficacy than the plasma concentrations and potency measured in standard growth inhibition assays and are better suited to determinations of whether one of the fluoroquinolones outperforms the others in rabbits with active TB. We first measured the penetration of these fluoroquinolones in lung lesion compartments, and their potency against bacterial populations that reside in each compartment, to compute lesion-centric pharmacokinetic-pharmacodynamic (PK/PD) parameters. PK modeling methods were used to quantify drug penetration from plasma to tissues at human-equivalent doses. On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin). A comparative efficacy trial in the rabbit model of active TB demonstrated the superiority of moxifloxacin in reducing bacterial burden at the lesion level and in sterilizing cellular and necrotic lesions. Collectively, these results show that PK/PD data obtained at the site of infection represent an adequate predictor of drug efficacy against TB and constitute the baseline required to explore synergies, antagonism, and drug-drug interactions in fluoroquinolone-containing regimens
Dynamic balance of pro‐ and anti‐inflammatory signals controls disease and limits pathology
Immune responses to pathogens are complex and not well understood in many diseases, and this is especially true for infections by persistent pathogens. One mechanism that allows for long‐term control of infection while also preventing an over‐zealous inflammatory response from causing extensive tissue damage is for the immune system to balance pro‐ and anti‐inflammatory cells and signals. This balance is dynamic and the immune system responds to cues from both host and pathogen, maintaining a steady state across multiple scales through continuous feedback. Identifying the signals, cells, cytokines, and other immune response factors that mediate this balance over time has been difficult using traditional research strategies. Computational modeling studies based on data from traditional systems can identify how this balance contributes to immunity. Here we provide evidence from both experimental and mathematical/computational studies to support the concept of a dynamic balance operating during persistent and other infection scenarios. We focus mainly on tuberculosis, currently the leading cause of death due to infectious disease in the world, and also provide evidence for other infections. A better understanding of the dynamically balanced immune response can help shape treatment strategies that utilize both drugs and host‐directed therapies.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146448/1/imr12671.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146448/2/imr12671_am.pd
Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models
The use of multi-scale mathematical and computational models to study complex biological processes is becoming increasingly productive. Multi-scale models span a range of spatial and/or temporal scales and can encompass multi-compartment (e.g., multi-organ) models. Modeling advances are enabling virtual experiments to explore and answer questions that are problematic to address in the wet-lab. Wet-lab experimental technologies now allow scientists to observe, measure, record, and analyze experiments focusing on different system aspects at a variety of biological scales. We need the technical ability to mirror that same flexibility in virtual experiments using multi-scale models. Here we present a new approach, tuneable resolution, which can begin providing that flexibility. Tuneable resolution involves fine- or coarse-graining existing multi-scale models at the user's discretion, allowing adjustment of the level of resolution specific to a question, an experiment, or a scale of interest. Tuneable resolution expands options for revising and validating mechanistic multi-scale models, can extend the longevity of multi-scale models, and may increase computational efficiency. The tuneable resolution approach can be applied to many model types, including differential equation, agent-based, and hybrid models. We demonstrate our tuneable resolution ideas with examples relevant to infectious disease modeling, illustrating key principles at work. WIREs Syst Biol Med 2014, 6:225–245. doi:10.1002/wsbm.1270 How to cite this article: WIREs Syst Biol Med 2014, 6:289–309. doi:10.1002/wsbm.127
Can systems immunology lead tuberculosis eradication?
25 years after the declaration of a Global Emergency by the World Health Organization, tuberculosis (TB) remains a major enemy to the humankind. During this period, much progress has been done to better understand its natural history, revealing its huge
complexity, which highlighted the need for implementing systems immunology approaches. Recent advances focused in understanding the role of macrophage subtypes and dendritic cells role, the importance of cytokine balance, and the antigenic repertoire. Identification of early irruption of polymorphonuclear neutrophils and extracellular growth of the bacilli seem to be the most disruptive factors to understand the evolution towards active TB. Their inclusion in future models will provide new tools for the better understanding of the tuberculosis.Peer ReviewedPostprint (published version
Neutrophil Dynamics Affect Mycobacterium tuberculosis Granuloma Outcomes and Dissemination
Neutrophil infiltration into tuberculous granulomas is often associated with higher bacteria loads and severe disease but the basis for this relationship is not well understood. To better elucidate the connection between neutrophils and pathology in primate systems, we paired data from experimental studies with our next generation computational model GranSim to identify neutrophil-related factors, including neutrophil recruitment, lifespan, and intracellular bacteria numbers, that drive granuloma-level outcomes. We predict mechanisms underlying spatial organization of neutrophils within granulomas and identify how neutrophils contribute to granuloma dissemination. We also performed virtual deletion and depletion of neutrophils within granulomas and found that neutrophils play a nuanced role in determining granuloma outcome, promoting uncontrolled bacterial growth in some and working to contain bacterial growth in others. Here, we present three key results: We show that neutrophils can facilitate local dissemination of granulomas and thereby enable the spread of infection. We suggest that neutrophils influence CFU burden during both innate and adaptive immune responses, implying that they may be targets for therapeutic interventions during later stages of infection. Further, through the use of uncertainty and sensitivity analyses, we predict which neutrophil processes drive granuloma severity and structure
Moving forward through the in silico modeling of tuberculosis : a further step with UISS-TB
In 2018, about 10 million people were found infected by tuberculosis, with approximately 1.2 million deaths worldwide. Despite these numbers have been relatively stable in recent years, tuberculosis is still considered one of the top 10 deadliest diseases worldwide. Over the years, Mycobacterium tuberculosis has developed a form of resistance to first-line tuberculosis treatments, specifically to isoniazid, leading to multi-drug-resistant tuberculosis. In this context, the EU and Indian DBT funded project STriTuVaD-In Silico Trial for Tuberculosis Vaccine Development-is supporting the identification of new interventional strategies against tuberculosis thanks to the use of Universal Immune System Simulator (UISS), a computational framework capable of predicting the immunity induced by specific drugs such as therapeutic vaccines and antibiotics. Here, we present how UISS accurately simulates tuberculosis dynamics and its interaction within the immune system, and how it predicts the efficacy of the combined action of isoniazid and RUTI vaccine in a specific digital population cohort. Specifically, we simulated two groups of 100 digital patients. The first group was treated with isoniazid only, while the second one was treated with the combination of RUTI vaccine and isoniazid, according to the dosage strategy described in the clinical trial design. UISS-TB shows to be in good agreement with clinical trial results suggesting that RUTI vaccine may favor a partial recover of infected lung tissue. In silico trials innovations represent a powerful pipeline for the prediction of the effects of specific therapeutic strategies and related clinical outcomes. Here, we present a further step in UISS framework implementation. Specifically, we found that the simulated mechanism of action of RUTI and INH are in good alignment with the results coming from past clinical phase IIa trials
Tumor Necrosis Factor-Regulated Granuloma Formation in Tuberculosis: Multi-Scale Modeling and Experiments.
Tuberculosis is a deadly infectious disease caused by Mycobacterium tuberculosis (Mtb). Multiple immune factors control host responses to Mtb infection, including the formation of granulomas in the lung, which are aggregates of bacteria, infected and uninfected immune cells whose function may reflect success or failure of the host to control infection. One such factor is tumor necrosis factor-α (TNF). TNF has been experimentally characterized to affect macrophage activation, apoptosis, chemokine and cytokine production during Mtb infection. Measurement of TNF concentrations and TNF activities within a granuloma to determine the relevant mechanisms for control of infection are difficult to assess in vivo. Further, processes that control TNF availability and activities within a granuloma remain unknown.
We developed a multi-scale computational model that describes the immune response to Mtb in lung over three biological length scales: tissue, cellular and molecular. We used the results of sensitivity analysis as a tool to identify which experiments were needed to measure critical model parameters in an experimental system. This system is a model of a granuloma induced in the lungs of mice following injection of mycobacterial antigen-coated beads. Using these parameters in the model, we identified processes that regulate TNF availability and cellular behaviors and thus influence the outcome of infection within a granuloma.
At the level of TNF/TNF receptor dynamics, TNF receptor internalization kinetics were shown to significantly influence TNF concentration dynamics, macrophage and T cell recruitment to site of infection, macrophage activation and apoptosis. These processes play a critical role in control of inflammation and bacterial levels within a granuloma. At the level of intracellular signaling, our analysis elucidated intracellular NF-κB associated signaling molecules and processes that may be new targets for control of infection and inflammation. We also used the model to explain what mechanisms lead to clinically observed differential effects of TNF-neutralizing drugs (generally used to treat inflammatory diseases) on reactivation of tuberculosis. Ultimately, these results can help to elaborate relevant features of the immune response to Mtb infection, identifying new strategies for therapy and prevention of tuberculosis as well as for development of safer anti-TNF drugs to treat inflammatory diseases.Ph.D.Chemical EngineeringUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttp://deepblue.lib.umich.edu/bitstream/2027.42/91477/1/fallahi_1.pd
A Simple In Vitro Bioassay Protocol Against Latent Phase Mycobacterial Cells
Pembangunan ubat-ubatan baru terhadap tuberkulosis (TB) terencat
disebabkan oleh kompleksiti protokol makmal asai pendam in vitro
Development of new drugs against latent tuberculosis (TB) is partly hindered
by the complexity of laboratory protocol for dormant in vitro assa
- …